| 2 -0.01 (-0.5%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.07  |
1-year : | 3.53 |
| Resists | First : | 2.63 |
Second : | 3.02 |
| Pivot price | 2.42 |
|||
| Supports | First : | 2 | Second : | 1.66 |
| MAs | MA(5) : | 2.22 |
MA(20) : | 2.44 |
| MA(100) : | 3 |
MA(250) : | 2.71 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 0.7 |
D(3) : | 9.9 |
| RSI | RSI(14): 32.6 |
|||
| 52-week | High : | 4.26 | Low : | 1.62 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TKNO ] has closed above bottom band by 0.9%. Bollinger Bands are 3.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.1 - 2.11 | 2.11 - 2.12 |
| Low: | 1.97 - 1.99 | 1.99 - 2 |
| Close: | 1.98 - 2 | 2 - 2.02 |
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
Wed, 13 Mar 2024
Earnings call: Teknova anticipates modest growth amid cost savings - Investing.com Canada
Mon, 11 Mar 2024
Alpha Teknova: Q4 Earnings Snapshot - Houston Chronicle
Thu, 29 Feb 2024
Alpha Teknova, Inc.'s (NASDAQ:TKNO) top owners are private equity firms with 63% stake, while 14% is held by ... - Yahoo Finance
Tue, 18 Oct 2022
10 Best Low Price Pharma Stocks To Buy Now - Yahoo Finance
Mon, 28 Feb 2022
Teknova Announces Preliminary Revenue of $10.0 to $10.1 Million for the Fourth Quarter 2021 - GlobeNewswire
Wed, 10 Nov 2021
Teknova Expands Leadership Team with the Appointments of Ken Gelhaus as Chief Commercial Officer and Jennifer ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 41 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 11.4 (%) |
| Held by Institutions | 77.3 (%) |
| Shares Short | 47 (K) |
| Shares Short P.Month | 54 (K) |
| EPS | -1.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.21 |
| Profit Margin | -100.3 % |
| Operating Margin | -124.5 % |
| Return on Assets (ttm) | -13.9 % |
| Return on Equity (ttm) | -38.8 % |
| Qtrly Rev. Growth | -0.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.89 |
| EBITDA (p.s.) | -0.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -1.73 |
| PEG Ratio | 0 |
| Price to Book value | 0.9 |
| Price to Sales | 2.22 |
| Price to Cash Flow | -4.35 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|